help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yew, W. W.
Right arrow Articles by Leung, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yew, W. W.
Right arrow Articles by Leung, C. C.
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 1324-1325, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.2502005


Editorial

Are Some People Not Safer after Successful Treatment of Tuberculosis?

Wing W. Yew, M.B. and Chi C. Leung, M.B.

Tuberculosis and Chest Unit, Grantham Hospital, Hong Kong, China

Contrary to the intuitive perception that previous tuberculosis often results in partial immunity (1), the study by Verver and coworkers (2) in this issue (pp. 1430–1435) demonstrates that the rate of reinfection tuberculosis after successful treatment is four times higher than the rate of new tuberculosis in an area with high prevalence of the disease. This novel finding is conceptually important because of its potential implications in tuberculosis control and vaccine development. Two possibilities exist to explain these results, neither of which is mutually exclusive: (1) the selection of individuals with predisposition to tuberculosis infection/disease or (2) that tuberculosis itself increases the vulnerability to reinfection/disease.

Disparate rates of tuberculosis infection have previously been demonstrated within different segments of population (3, 4). Increased susceptibility to development of disease is also well reported among various patient groups (5, 6). In a recent study in Hong Kong, men aged 65 years or older who smoke were shown to have an incidence of tuberculosis seven times greater than that of the general population (7). Increased rates of tuberculosis in a population subset may result in an apparent increase of recurrent tuberculosis in patients after successful treatment. To take a simple example, if 20% of the community has an incidence of disease three times that of the general population, then this high-risk segment will be overrepresented in the tuberculosis patient population (3 x 20% = 60%), and the incidence of disease among the entire patient group will appear to be increased by twofold. After an episode of tuberculosis, "negative" immunity with increased vulnerability to development of disease might be rather unlikely, but increased risk of exposure may still arise within the health care settings. Indeed, the lower incidence of reinfection disease noted in Verver and colleagues' study among the defaulters, who interrupted treatment for a minimum of 2 months or were never treated, is consistent with this possibility.

A few caveats must also be borne in mind when interpreting the findings of this epidemiologic study. First, the percentage of available DNA fingerprints is relatively low (70%) as compared with another population-based study of a similar nature (8), as is the substantial percentage of solitary positive cultures in comparison to other studies (5). Although it would not be fair to speculate on the magnitude of false-positive cultures, such a possibility could exist. On the other hand, Verver and colleagues state that their laboratory error rate was only 3.4%, a figure that indeed closely corroborates the findings of another study that has addressed DNA fingerprint changes in tuberculosis (8). They also stress that, after excluding those episodes with single-positive cultures from the analysis, there is still a similar proportion of recurrences attributed to reinfection: 71% after successful treatment and 13% after default. However, after excluding cases with single-positive cultures, disease rates related to confirmed or likely reinfection were much lower, being only approximately twice the age-adjusted incidence rate of new tuberculosis for the entire population of the community. Second, although some characteristics of the study cases with available DNA fingerprints have been provided, other possible confounders, such as HIV status or socioeconomic background, were not investigated among the study patients and compared with the overall population (35, 9).

HIV infection is a risk factor for both endogenous relapse of tuberculosis and rapid progression to disease after exogenous tuberculosis infection. The relative contribution of each process will determine the relationship with clustering. Some studies have found an increased risk for tuberculosis clustering among patients with HIV (10, 11), but others have found no association between HIV infection and such clustering (1214). A recent investigation undertaken in northern Malawi in Africa has revealed that a higher proportion of recurrent tuberculosis caused by reinfection after treatment occurred among HIV-positive individuals than HIV-negative subjects: 58 versus 0% (8). Furthermore, a study conducted in African mineworkers has revealed HIV infection as a risk factor for recurrence of tuberculosis after cure (hazard ratio, 2.4) because of its strong association with disease caused by reinfection (hazard ratio, 18.7), but not relapse (hazard ratio, 0.58) (5). Thus, assessment of factors such as secondary chemoprophylaxis and/or antiretroviral treatment was suggested for these subjects.

Verver and coworkers have alluded to the scenario of dual infection with M. tuberculosis, of which one strain was cultivable during the first disease episode, and the other strain during the recurrent episode. Distinguishing between "new" reinfection and dual infection initially followed by such reactivation of one strain may not be easy. Nevertheless, the likelihood of tuberculosis caused by multiple strains fortunately does not appear to be high (<= 20%), and findings from molecular epidemiologic studies still provide reasonably valid information (15).

The messages derived from the present study might merit exploration in tuberculosis program enhancement, especially regarding case finding and preventive therapy among at-risk population groups in areas of high disease prevalence. Most phase III trials on new antituberculosis drugs rely on recruitment from these areas, and use bacteriologic relapse as the primary endpoint to assess chemotherapy efficacy. If over two-thirds of such "relapses" are not true relapses, validation with molecular techniques may be necessary.

FOOTNOTES

Conflict of Interest Statement: W.W.Y. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; C.C.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

REFERENCES

  1. Hart PD, Sutherland I. Acquired immunity to tuberculosis. Am Rev Respir Dis 1965;91:939.
  2. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson DA, Behr MA, van Helden PD. The rate of reinfection tuberculosis after treatment is higher than the rate of new tuberculosis. Am J Respir Crit Care Med 2005;171:1430–1435.[Abstract/Free Full Text]
  3. Centers for Disease Control and Prevention. Racial disparities in tuberculosis—selected Southeastern states, 1991–2002. MMWR Morb Mortal Wkly Rep 2004;53:556–559.[Medline]
  4. Austin JF, Dick JM, Zwarenstein M. Gender disparity amongst TB suspects and new TB patients according to data recorded at the South African Institute of Medical Research laboratory for the Western Cape Region of South Africa. Int J Tuberc Lung Dis 2004;8:435–439.[Medline]
  5. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687–1693.[CrossRef][Medline]
  6. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36–41.[Medline]
  7. Leung CC, Li T, Lam TH, Yew WW, Law WS, Tam CM, Chan WM, Chan CK, Ho KS, Chang KC. Smoking and tuberculosis among the elderly in Hong Kong. Am J Respir Crit Care Med 2004;170:1027–1033.[Abstract/Free Full Text]
  8. Glynn JR, Yates MD, Crampin AC, Ngwira BM, Mwaungulu FD, Black GF, Chaguluka SD, Mwafulirwa DT, Floyd S, Murphy C, et al. DNA fingerprint changes in tuberculosis: reinfection, evolution, or laboratory error? J Infect Dis 2004;190:1158–1166.[CrossRef][Medline]
  9. Leung CC, Yew WW, Tam CM, Chan CK, Chang KC, Law WS, Wong MY, Au KF. Socio-economic factors and tuberculosis: a district-based ecological analysis in Hong Kong. Int J Tuberc Lung Dis 2004;8:958–964.[Medline]
  10. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, Schecter GF, Daley CL, Schoolnik GK. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703–1709.[Abstract/Free Full Text]
  11. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom BR. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710–1716.[Abstract/Free Full Text]
  12. Barnes PF, Yang Z, Pogoda JM, Preston-Martin S, Jones BE, Otaya M, Knowles L, Harvey S, Eisenach KD, Caves MD. Foci of tuberculosis transmission in central Los Angeles. Am J Respir Crit Care Med 1999;159:1081–1086.[Abstract/Free Full Text]
  13. Lockman S, Sheppard JD, Braden CR, Mwasekaga MJ, Woodley CL, Kenyon TA, Binkin NJ, Steinman M, Montsho F, Kesupile-Reed M, et al. Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population-based prospective study of 301 pulmonary tuberculosis patients. J Clin Microbiol 2001;39:1042–1047.[Abstract/Free Full Text]
  14. Godfrey-Faussett P, Sonnenberg P, Shearer SC, Bruce MC, Mee C, Morris L, Murray J. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000;356:1066–1071.[CrossRef][Medline]
  15. Behr MA. Tuberculosis due to multiple strains: a concern for the patient? A concern for tuberculosis control? Am J Respir Crit Care Med 2004;169:554–555.[Free Full Text]



This article has been cited by other articles:


Home page
Clin. Microbiol. Rev.Home page
B. Mathema, N. E. Kurepina, P. J. Bifani, and B. N. Kreiswirth
Molecular Epidemiology of Tuberculosis: Current Insights
Clin. Microbiol. Rev., October 1, 2006; 19(4): 658 - 685.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. W. Yew and C. C. Leung
Update in tuberculosis 2005.
Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 491 - 498.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yew, W. W.
Right arrow Articles by Leung, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yew, W. W.
Right arrow Articles by Leung, C. C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society